Join

Compare · AEMD vs DXCM

AEMD vs DXCM

Side-by-side comparison of Aethlon Medical Inc. (AEMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AEMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $29.57B, about 6230.4x AEMD ($4.7M).
  • Over the past year, AEMD is down 99.2% and DXCM is down 10.6% - DXCM leads by 88.6 points.
  • DXCM has been more active in the news (26 items in the past 4 weeks vs 4 for AEMD).
  • DXCM has more recent analyst coverage (25 ratings vs 2 for AEMD).
PerformanceAEMD-99.20%DXCM-10.56%
2025-06-09+0.00%2026-06-08
MetricAEMDDXCM
Company
Aethlon Medical Inc.
DexCom Inc.
Price
$2.03+2.53%
$76.59+5.15%
Market cap
$4.7M
$29.57B
1M return
-10.57%
+25.71%
1Y return
-99.20%
-10.56%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
News (4w)
4
26
Recent ratings
2
25
AEMD

Aethlon Medical Inc.

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Latest AEMD

Latest DXCM